Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Refractory Generalized Myasthenia Gravis
NCT07058298Phase 1Recruiting
- Sponsor
- Daishi Tian
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in myasthenia gravis (MG), sponsored by Daishi Tian. Primary endpoint: Frequency and severity of adverse events at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07058298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058298.